Everolimus in advanced, progressive, well‐differentiated, non‐functional neuroendocrine tumors: RADIANT‐4 lung subgroup analysis

In the phase III RADIANT‐4 study, everolimus improved median progression‐free survival (PFS) by 7.1 months in patients with advanced, progressive, well‐differentiated (grade 1 or grade 2), non‐functional lung or gastrointestinal neuroendocrine tumors (NETs) vs placebo (hazard ratio, 0.48; 95% confid...

Descripción completa

Detalles Bibliográficos
Autores principales: Fazio, Nicola, Buzzoni, Roberto, Delle Fave, Gianfranco, Tesselaar, Margot E., Wolin, Edward, Van Cutsem, Eric, Tomassetti, Paola, Strosberg, Jonathan, Voi, Maurizio, Bubuteishvili‐Pacaud, Lida, Ridolfi, Antonia, Herbst, Fabian, Tomasek, Jiri, Singh, Simron, Pavel, Marianne, Kulke, Matthew H., Valle, Juan W., Yao, James C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5765303/
https://www.ncbi.nlm.nih.gov/pubmed/29055056
http://dx.doi.org/10.1111/cas.13427

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5765303/
https://www.ncbi.nlm.nih.gov/pubmed/29055056
http://dx.doi.org/10.1111/cas.13427

Ejemplares similares